US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist
  • 8.250
  • -0.150-1.79%
Trading Dec 27 10:37 ET
161.14MMarket Cap-5.66P/E (TTM)

Actuate Therapeutics Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
Total revenue
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-16.72%5.39M
-2.67%5.44M
46.71%7.77M
23.59%24.97M
7.62M
6.48M
5.58M
5.3M
20.21M
Selling and administrative expenses
129.05%1.64M
31.65%1.06M
17.81%912.82K
-14.51%3.27M
--969.35K
--714.17K
--807.18K
--774.8K
--3.82M
-General and administrative expense
129.05%1.64M
31.65%1.06M
17.81%912.82K
-14.51%3.27M
--969.35K
--714.17K
--807.18K
--774.8K
--3.82M
Research and development costs
-34.79%3.76M
-8.47%4.37M
51.65%6.86M
32.47%21.71M
--6.65M
--5.76M
--4.78M
--4.52M
--16.39M
Operating profit
16.72%-5.39M
2.67%-5.44M
-46.71%-7.77M
-23.59%-24.97M
-7.62M
-6.48M
-5.58M
-5.3M
-20.21M
Net non-operating interest income expense
-36.09%77.26K
-96.77%3.57K
-58.14%9.71K
2,754.26%309.03K
54.63K
120.88K
110.33K
23.2K
10.83K
Non-operating interest income
-35.89%80.75K
-92.51%8.65K
-71.37%14.79K
1,204.89%352.67K
--59.69K
--125.94K
--115.39K
--51.65K
--27.03K
Non-operating interest expense
-31.07%3.49K
0.28%5.08K
-82.16%5.08K
169.39%43.64K
--5.06K
--5.06K
--5.06K
--28.45K
--16.2K
Other net income (expense)
-3,985.43%-655.32K
-2,171.86%-1.14M
-10,533.29%-532.52K
-318.22%-79.82K
-51.6K
16.87K
-50.19K
5.1K
36.58K
Gain on sale of security
3,085.05%537.19K
-378.82%-240.34K
-737.05%-32.52K
-318.22%-79.82K
---51.6K
--16.87K
---50.19K
--5.1K
--36.58K
Other non- operating income (expenses)
---1.19M
---900K
---500K
----
----
----
----
----
----
Income before tax
5.79%-5.97M
-18.97%-6.57M
-57.41%-8.3M
-22.74%-24.74M
-7.61M
-6.34M
-5.52M
-5.27M
-20.16M
Income tax
Net income
5.79%-5.97M
-18.97%-6.57M
-57.41%-8.3M
-22.74%-24.74M
-7.61M
-6.34M
-5.52M
-5.27M
-20.16M
Net income continuous Operations
5.79%-5.97M
-18.97%-6.57M
-57.41%-8.3M
-22.74%-24.74M
---7.61M
---6.34M
---5.52M
---5.27M
---20.16M
Minority interest income
Net income attributable to the parent company
5.79%-5.97M
-18.97%-6.57M
-57.41%-8.3M
-22.74%-24.74M
-7.61M
-6.34M
-5.52M
-5.27M
-20.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
5.79%-5.97M
-18.97%-6.57M
-57.41%-8.3M
-22.74%-24.74M
-7.61M
-6.34M
-5.52M
-5.27M
-20.16M
Basic earnings per share
-34.42%-0.55
3.58%-0.3439
-58.71%-0.54
-23.05%-1.65
-0.3983
-0.4092
-0.3566
-0.3402
-1.3409
Diluted earnings per share
-34.42%-0.55
3.58%-0.3439
-58.71%-0.54
-23.05%-1.65
-0.3983
-0.4092
-0.3566
-0.3402
-1.3409
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023(FY)Dec 31, 2022
Total revenue 000000000
Operating revenue --0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -16.72%5.39M-2.67%5.44M46.71%7.77M23.59%24.97M7.62M6.48M5.58M5.3M20.21M
Selling and administrative expenses 129.05%1.64M31.65%1.06M17.81%912.82K-14.51%3.27M--969.35K--714.17K--807.18K--774.8K--3.82M
-General and administrative expense 129.05%1.64M31.65%1.06M17.81%912.82K-14.51%3.27M--969.35K--714.17K--807.18K--774.8K--3.82M
Research and development costs -34.79%3.76M-8.47%4.37M51.65%6.86M32.47%21.71M--6.65M--5.76M--4.78M--4.52M--16.39M
Operating profit 16.72%-5.39M2.67%-5.44M-46.71%-7.77M-23.59%-24.97M-7.62M-6.48M-5.58M-5.3M-20.21M
Net non-operating interest income expense -36.09%77.26K-96.77%3.57K-58.14%9.71K2,754.26%309.03K54.63K120.88K110.33K23.2K10.83K
Non-operating interest income -35.89%80.75K-92.51%8.65K-71.37%14.79K1,204.89%352.67K--59.69K--125.94K--115.39K--51.65K--27.03K
Non-operating interest expense -31.07%3.49K0.28%5.08K-82.16%5.08K169.39%43.64K--5.06K--5.06K--5.06K--28.45K--16.2K
Other net income (expense) -3,985.43%-655.32K-2,171.86%-1.14M-10,533.29%-532.52K-318.22%-79.82K-51.6K16.87K-50.19K5.1K36.58K
Gain on sale of security 3,085.05%537.19K-378.82%-240.34K-737.05%-32.52K-318.22%-79.82K---51.6K--16.87K---50.19K--5.1K--36.58K
Other non- operating income (expenses) ---1.19M---900K---500K------------------------
Income before tax 5.79%-5.97M-18.97%-6.57M-57.41%-8.3M-22.74%-24.74M-7.61M-6.34M-5.52M-5.27M-20.16M
Income tax
Net income 5.79%-5.97M-18.97%-6.57M-57.41%-8.3M-22.74%-24.74M-7.61M-6.34M-5.52M-5.27M-20.16M
Net income continuous Operations 5.79%-5.97M-18.97%-6.57M-57.41%-8.3M-22.74%-24.74M---7.61M---6.34M---5.52M---5.27M---20.16M
Minority interest income
Net income attributable to the parent company 5.79%-5.97M-18.97%-6.57M-57.41%-8.3M-22.74%-24.74M-7.61M-6.34M-5.52M-5.27M-20.16M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 5.79%-5.97M-18.97%-6.57M-57.41%-8.3M-22.74%-24.74M-7.61M-6.34M-5.52M-5.27M-20.16M
Basic earnings per share -34.42%-0.553.58%-0.3439-58.71%-0.54-23.05%-1.65-0.3983-0.4092-0.3566-0.3402-1.3409
Diluted earnings per share -34.42%-0.553.58%-0.3439-58.71%-0.54-23.05%-1.65-0.3983-0.4092-0.3566-0.3402-1.3409
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSD
Trending US Stocks
U.S Tech Companies U.S Tech Companies

U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.